Bluebird Bio To Present At The Cowen And Company Health Care Conference
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present
at the Cowen and Company 34
th Annual Health Care Conference
to be held March 2 - 5, 2014 at the Boston Marriott Copley Place Hotel,
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Cowen and Company 34 th Annual Health Care Conference to be held March 2 - 5, 2014 at the Boston Marriott Copley Place Hotel, Boston, MA. Nick Leschly, Chief bluebird, will provide an overview of the company at the conference on Tuesday, March 4, 2014 at 8:00 AM (ET). To access a simultaneous webcast of Mr. Leschly's overview via the internet, log on to the "Calendar of Events" section on the Investor and Media page of the bluebird bio's website at http://investor.bluebirdbio.com. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast. A replay of the webcasts will be available on bluebird bio's website for ninety days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Calendar of Events" section of the Investor and Media page of the bluebird bio's website at http://investor.bluebirdbio.com. About bluebird bio, Inc. bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, is in a recently-initiated phase 2/3 study for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in a phase 1/2 study in France for the treatment of beta-thalassemia major and severe sickle cell disease. A second phase 1/2 study with LentiGlobin in the United States has been initiated for the treatment of beta-thalassemia major. bluebird bio also has an early-stage chimeric antigen receptor-modified T cell (CAR-T) program for oncology in partnership with Celgene Corporation.